{"id":71446,"date":"2026-05-20T11:50:00","date_gmt":"2026-05-20T11:50:00","guid":{"rendered":"https:\/\/medsbase.com\/aod-9604\/"},"modified":"2026-10-15T10:33:56","modified_gmt":"2026-10-15T10:33:56","slug":"aod-9604","status":"publish","type":"product","link":"https:\/\/medsbase.com\/de\/product\/aod-9604\/","title":{"rendered":"AOD-9604 (Anti-Obesity-Drug 9604 \/ Tyr-hGH 177-191)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Kurze Antwort \u2014 Was ist AOD-9604?<\/h3>\n<p style=\"margin: 0;\"><strong>AOD-9604<\/strong> (\u201cAnti-Obesity Drug 9604\u201d, CAS 221231-10-3) ist ein synthetisches 16-Aminos\u00e4ure-Peptid, das von <strong>Metabolic Pharmaceuticals Ltd<\/strong> (Australien) in den sp\u00e4ten 1990er Jahren als stabilisiertes Analogon des C-terminalen lipolytischen Fragments des menschlichen Wachstumshormons entwickelt wurde. Sequenz Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (16 aa, mit einer N-terminalen Tyrosin-Erweiterung, die das urspr\u00fcngliche hGH 177\u2013191-Fragment stabilisiert, und einer Cys7\u2013Cys14 intramolekularen Disulfidbr\u00fccke). Molek\u00fclformel C, MW 1815,1 Da. In ver\u00f6ffentlichter In-vitro- und Nagetierforschung beh\u00e4lt AOD-9604 die<sub>78<\/sub>H<sub>123<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub>, MW 1815.1 Da. In published in-vitro and rodent studies AOD-9604 retains the <strong>des urspr\u00fcnglichen hGH-Molek\u00fcls bei, bindet jedoch nicht<\/strong> des Elternmolek\u00fcls hGH, tut dies jedoch nicht <em>nicht<\/em> bind the GH receptor \u2014 so it does not induce IGF-1, does not activate growth-axis JAK2\/STAT5 signalling, and does not produce the growth-promoting effects of full-length HGH. Failed Phase IIb obesity trial (2007); now used as a pharmaceutical-grade peptide. <em>For clinical studies use only.<\/em><\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Was Sie bei MedsBase erhalten:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/de\/reviews\/\">Kundenbewertungen<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Jede Bestellung ist durch unsere <a href=\"https:\/\/medsbase.com\/de\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> abgedeckt \u2014 wenn Ihr Paket nicht innerhalb von 20 Werktagen ankommt, versenden wir es erneut.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Spezifikation<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Verbindungsklasse<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Synthetic 16-amino-acid peptide; stabilised C-terminal hGH-fragment analogue; lipolytic \/ anti-lipogenic peptide (decoupled from GH-receptor binding)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Chemischer Name<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">AOD-9604 (\u201cAnti-Obesity Drug 9604\u201d; Synonyme: Tyr-hGH 177-191; H-Tyr-(177-191 hGH-Fragment)-OH)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS-Nummer<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">221231-10-3 (kanonische Referenz Sigma-Aldrich, MedKoo, ChemicalBook)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Molekularformel<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>78<\/sub>H<sub>123<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Molekulargewicht<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1815.1 g\/mol<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequenz<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (Einbuchstabencode: YLRIVQCRSVEGSCGF; 16 Aminos\u00e4uren). Die intramolekulare Disulfidbr\u00fccke Cys7\u2013Cys14 bildet eine zyklische Struktur, die die Disulfidgeometrie der parentalen hGH 182\u2013189-Region nachahmt. Das N-terminale Tyrosin ist eine synthetische Zugabe (in nativen hGH 177\u2013191 nicht vorhanden), die das Fragment gegen amino-terminalen proteolytischen Abbau stabilisiert.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Mechanismus<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\"><strong>Mechanisch entkoppelte Lipolyse<\/strong>. AOD-9604 bindet NICHT an den GH-Rezeptor (GHR) \u2014 die GHR-bindende Oberfl\u00e4che des nativen hGH liegt im N-terminalen Teil (Region der Reste 1\u2013120), der im 176\u2013191-Fragment fehlt. Die lipolytische \/ anti-lipogene Aktivit\u00e4t wird vermutlich \u00fcber die \u03b23-adrenerge Rezeptorsignalgebung und die direkte Aktivierung der hormonsensitiven Lipase (HSL) der Adipozyten \u00fcber cAMP-PKA vermittelt. Der Mechanismus bleibt in der ver\u00f6ffentlichten Literatur unvollst\u00e4ndig charakterisiert \u2014 es gibt keinen einzigen best\u00e4tigten Rezeptor f\u00fcr das C-terminale lipolytische Fragment.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Plasmahalbwertszeit<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~4 Minuten (sehr kurz \u2013 verursacht durch N-terminale proteolytische Abspaltung trotz der stabilisierenden Tyr). Diese kurze Halbwertszeit ist eine der f\u00fchrenden Hypothesen, warum die Phase-IIb-Adipositas-Studie (2007) die Gewichtsverlust-Endpunkte nicht erreichte \u2013 das Fragment wird abgebaut, bevor sich eine ausreichende Rezeptorexposition im Zielgewebe ansammeln kann.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Form<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white amorphous powder; single-use vials<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Reinheit<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC-best\u00e4tigt); MALDI-TOF-Massenspektrometrie best\u00e4tigt 1815,1 Da. Analysezertifikat auf Anfrage erh\u00e4ltlich.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>L\u00f6slichkeit<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">L\u00f6slich in bakterienstatischem Wasser, sterilem Wasser, PBS und 0,1%iger Essigs\u00e4ure bei \u22655 mg\/mL; leicht l\u00f6slich in DMSO bei \u226550 mg\/mL f\u00fcr die In-vitro-Stamml\u00f6sungsherstellung. Die Cys7\u2013Cys14-Disulfidbr\u00fccke begrenzt die Peptidgeometrie, beeintr\u00e4chtigt jedoch nicht die w\u00e4ssrige L\u00f6slichkeit.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Lagerung<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilisat: 2\u20138 \u00b0C unge\u00f6ffnet f\u00fcr kurzfristige Arbeitsvorr\u00e4te; \u221220 \u00b0C f\u00fcr Langzeitlagerung (stabil \u226536 Monate bei \u221220 \u00b0C; \u226518 Monate bei 2\u20138 \u00b0C). Rekonstituierte w\u00e4ssrige L\u00f6sung: 2\u20138 \u00b0C, innerhalb von ~30 Tagen verwenden. Lichtschutz beachten. Wiederholte Gefrier-Tau-Zyklen der rekonstituierten L\u00f6sung vermeiden \u2013 die Disulfidbr\u00fccke ist stabil gegen\u00fcber einmaligem Gefrier-Tau, aber kumulative Zyklen k\u00f6nnen zu Thiol-Scrambling und partieller Aggregation f\u00fchren.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Was ist AOD-9604?<\/h2>\n<p><strong>AOD-9604<\/strong> (\u201cAnti-Obesity Drug 9604\u201d; CAS 221231-10-3) ist ein synthetisches 16-Aminos\u00e4ure-Peptid, entwickelt von <strong>Metabolic Pharmaceuticals Ltd<\/strong> an der Monash University in Melbourne, Australien, ab Ende der 1990er Jahre. Es handelt sich um ein stabilisiertes Analogon des C-terminalen lipolytischen Fragments des nativen menschlichen Wachstumshormons (Rest 177\u2013191), dem eine N-terminale Tyrosin hinzugef\u00fcgt wurde, um die aminoterminale proteolytische Degradation zu verlangsamen. Sequenz Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF), wobei die native Cys182\u2013Cys189-Disulfidbr\u00fccke des Eltern-hGH als Cys7\u2013Cys14 innerhalb der Fragmentnummerierung erhalten bleibt. Molekulargewicht 1815,1 g\/mol, Summenformel C<sub>78<\/sub>H<sub>123<\/sub>N<sub>23<\/sub>O<sub>23<\/sub>S<sub>2<\/sub>. The pharmacological logic behind AOD-9604 is one of the cleanest examples of structure-function dissection in HGH peptide studies. Native full-length human growth hormone (191 amino acids) has at least two distinct biological activities: <strong>wachstumsf\u00f6rdernde\/anabole Effekte<\/strong> (vermittelt durch den GH-Rezeptor, JAK2\/STAT5-Signalweg und nachgeschaltete IGF-1-Produktion) und <strong>lipolytische\/anti-lipogene Effekte<\/strong> (mediated through a separate, incompletely-characterised mechanism that does not require GH-receptor engagement). The Monash group&#8217;s hypothesis was that the lipolytic activity is encoded in the C-terminal region of the molecule \u2014 and that a synthetic peptide encompassing just that region might retain the fat-mobilising activity while losing the growth-axis-engaging activity. This proved correct in published in-vitro and rodent studies: the 176\u2013191 fragment retains lipolytic and anti-lipogenic activity in adipocyte culture and DIO mouse models, but does not bind GHR, does not activate JAK2\/STAT5, and does not induce IGF-1. AOD-9604 progressed through multiple Phase I and Phase II clinical trials in the early-to-mid 2000s, culminating in a 28-week Phase IIb obesity trial (~500 patients) completed in 2007 by Metabolic Pharmaceuticals. The trial did not achieve its primary weight-loss endpoint, and the obesity-pharmacology development programme was discontinued. AOD-9604 subsequently entered the studies-peptide and unregulated-supplement markets, where it has remained one of the most-cited &#8220;fat-loss peptides&#8221; in non-clinical literature. The compound retains studies utility as the canonical pharmacological tool for studying GHR-decoupled lipolysis, the C-terminal hGH fragment biology, and the structure-function basis of HGH&#8217;s multiple activities. A note on nomenclature: AOD-9604 and &#8220;<a href=\"https:\/\/medsbase.com\/de\/hgh-fragment-176-191\/\">HGH Fragment 176-191<\/a>&#8221; are often used interchangeably in the supplier and studies-peptide marketplace. Strictly, AOD-9604 (CAS 221231-10-3) is the Metabolic-Pharmaceuticals-developed analogue with the N-terminal Tyr stabilisation. &#8220;HGH Fragment 176-191&#8221; (CAS 66004-57-7 per some references) is the older, un-stabilised hGH 177\u2013191 fragment that AOD-9604 was derived from. Both share the same YLRIVQCRSVEGSCGF amino-acid sequence in many supplier preparations \u2014 but the AOD-9604 designation specifically identifies the registered Metabolic-Pharmaceuticals compound. Users should consult the COA to confirm which form a given supplier batch corresponds to. <\/p>\n<h2>Mechanismus der Wirkung \u2014 GHR-entkoppelte Lipolyse<\/h2>\n<p>AOD-9604&#8217;s mechanism is among the most-discussed in HGH peptide studies:<\/p>\n<ul>\n<li><strong>Fehlende GH-Rezeptorbindung<\/strong> \u2014 Die GHR-bindende Oberfl\u00e4che des nativen hGH befindet sich in der N-terminalen H\u00e4lfte des Molek\u00fcls (Region der Reste 1\u2013120), die im AOD-9604 \/ 176\u2013191-Fragment fehlt. Folglich bindet AOD-9604 NICHT an den Wachstumshormonrezeptor (GHR), aktiviert NICHT die JAK2\/STAT5-Signalgebung, induziert NICHT die hepatische IGF-1-Produktion und bewirkt NICHT die wachstumsf\u00f6rdernden, chondrozytenstimulierenden oder insulin-gegenregulatorischen Effekte des Ausgangs <a href=\"https:\/\/medsbase.com\/de\/hgh-191aa\/\">HGH 191AA<\/a> molek\u00fcls. Dies ist die definierende <em>negative<\/em> pharmacological property and the basis for AOD-9604&#8217;s studies utility as a lipolysis-axis-isolating tool.<\/li>\n<li><strong>\u03b23-adrenerge Rezeptorsignalgebung (hypothesiert)<\/strong> \u2014 The leading mechanistic hypothesis for AOD-9604&#8217;s lipolytic activity is that it engages the \u03b23-adrenergic receptor (ADRB3) on adipocytes, either directly as an allosteric modulator or via an intermediate pathway. Published in-vitro has demonstrated that AOD-9604&#8217;s lipolytic effect is blunted by \u03b23-adrenergic antagonists, supporting the \u03b23-AR hypothesis, although direct AOD-9604 \/ \u03b23-AR binding has not been conclusively demonstrated in radioligand-binding assays. The mechanism remains incompletely characterised \u2014 a feature users should be aware of when interpreting published AOD-9604 results.<\/li>\n<li><strong>Aktivierung der hormonsensitiven Lipase (HSL)<\/strong> \u2014 Downstream der Rezeptorbindung wurde berichtet, dass AOD-9604 die hormonsensitive Lipase der Adipozyten \u00fcber eine PKA-vermittelte Phosphorylierung (der kanonische Lipolyse-Aktivierungsweg) aktiviert, was die Hydrolyse von Triglyceriden in Glycerin und freie Fetts\u00e4uren antreibt. Der Anstieg der Freisetzung von freien Fetts\u00e4uren in den Kreislauf wurde in ver\u00f6ffentlichten in-vivo-Studien an Nagetieren nach der Verabreichung von AOD-9604 dokumentiert.<\/li>\n<li><strong>Anti-lipogene Aktivit\u00e4t<\/strong> \u2014 Neben der F\u00f6rderung der Lipolyse wurde berichtet, dass AOD-9604 die de-novo-Lipogenese in kultivierten Adipozyten unterdr\u00fcckt \u2014 es reduziert die Aktivit\u00e4t der Acetyl-CoA-Carboxylase (ACC) und der Fetts\u00e4ure-Synthase (FAS) in 3T3-L1-Differenzierungsassays. Das kombinierte Profil aus gesteigerter Lipolyse und reduzierter Lipogenese ist die kanonische \u201cFettmobilisierungs\u201d-Pharmakologie, die das urspr\u00fcngliche Metabolic-Pharmaceuticals-Programm anstreben sollte.<\/li>\n<li><strong>Cartilage \/ osteoarthritis studies (secondary indication)<\/strong> \u2014 Following the failure of the obesity programme, AOD-9604 was repositioned for evaluation in osteoarthritis studies, with the hypothesis that chondroprotective effects of the parent hGH might be partially retained in the C-terminal fragment. Published in-vitro and small-animal has reported chondrocyte-protective effects, although no large clinical trial in this indication has been completed.<\/li>\n<li><strong>Das Problem der 4-min\u00fctigen Halbwertszeit<\/strong> \u2014 AOD-9604&#8217;s plasma half-life is approximately 4 minutes, driven by rapid amino-terminal proteolytic truncation despite the N-terminal Tyr stabilisation. This very short pharmacokinetic profile is one of the leading hypotheses for why the Phase IIb obesity trial did not achieve weight-loss endpoints \u2014 the fragment is degraded before sufficient receptor exposure can accumulate in target adipose tissue under once-daily SC dosing. Newer peptides that target the same lipolysis-axis biology with longer half-lives (modified hGH fragments with PEG-stabilisation, fragment-Fc fusion proteins) are in earlier-stage studies and not commercially available.<\/li>\n<\/ul>\n<p>The combination of mechanistically clean GHR-decoupling and disappointing in-vivo half-life makes AOD-9604 a useful tool with a clear pharmacological story but a documented translational limitation. Published studies dosing in rodents is typically 100\u20131,000 \u00b5g\/kg\/d SC, with the higher end of this range used to overcome the short half-life by saturating clearance. In cell-culture work, micromolar concentrations are used because of the short biological half-life of the fragment in culture medium. <\/p>\n<h2>Published Evidence<\/h2>\n<p>AOD-9604 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>GHR-entkoppelte Lipolyse-Pharmakologie<\/strong> \u2014 the canonical tool for studying the lipolytic \/ anti-lipogenic activity of the C-terminal hGH fragment in isolation from GH-axis signalling; standard reference compound for any new &#8220;fat-loss-only&#8221; hGH-fragment studies<\/li>\n<li><strong>Structure-function studies of HGH<\/strong> \u2014 AOD-9604 is one of the cleanest examples of pharmacological structure-function dissection of the multi-activity HGH molecule; used in published studies that maps the lipolytic-domain residues of native HGH<\/li>\n<li><strong>Adipocyte biology and lipolysis studies<\/strong> \u2014 drives lipolysis in cultured 3T3-L1 and primary adipocyte preparations; used in studies on the regulation of adipocyte hormone-sensitive lipase, lipid droplet remodelling, and brown \/ beige adipocyte biology<\/li>\n<li><strong>\u03b23-adrenerge Rezeptorpharmakologie (indirekt)<\/strong> \u2014 AOD-9604&#8217;s \u03b23-AR-dependence (in some published studies) makes it useful as an indirect probe of \u03b23-AR-coupled lipolysis pathways, alongside direct \u03b23-AR agonists (CL-316,243, mirabegron)<\/li>\n<li><strong>Diet-induced obesity (DIO) rodent studies<\/strong> \u2014 published 4\u20138 week dosing protocols (100\u20131,000 \u00b5g\/kg\/d SC) in DIO mice and rats have been reported to reduce fat-mass without affecting lean-mass or IGF-1 levels; standard tool for the &#8220;lipolytic-only&#8221; component of fat-loss pharmacology<\/li>\n<li><strong>Cartilage \/ chondrocyte studies<\/strong> \u2014 used in published in-vitro chondrocyte and small-animal osteoarthritis models for chondroprotective evaluation; secondary studies indication following the discontinuation of the obesity programme<\/li>\n<li><strong>Vergleichende Pharmakologie vs. HGH 191AA und HGH-Fragment 176-191<\/strong> \u2014 ver\u00f6ffentlichte direkte Vergleiche von AOD-9604 mit vollst\u00e4ndigem HGH und dem nicht-stabilisierten 176-191-Fragment haben die unterschiedlichen GHR-Bindungs-, IGF-1-Induktions- und Lipolyseprofile charakterisiert; AOD-9604 steht am Ende \u201crein lipolytisch, ohne Wachstumsachse\u201d dieses Spektrums<\/li>\n<li><strong>Plasma-stability and protease-resistance studies<\/strong> \u2014 the 4-minute half-life makes AOD-9604 a useful reference compound for protease-resistance studies; newer modified analogues (PEG-stabilised, fragment-Fc fusion, alternative N-terminal cap modifications) are benchmarked against AOD-9604 in early-stage development studies<\/li>\n<\/ul>\n<p>For broader context on HGH-axis and fat-loss peptides in this catalogue, see <a href=\"https:\/\/medsbase.com\/de\/hgh-fragment-176-191\/\">HGH Fragment 176-191<\/a> (das nicht-stabilisierte Elternfragment \u2013 direkter Vergleich), <a href=\"https:\/\/medsbase.com\/de\/hgh-191aa\/\">HGH 191AA<\/a> (das vollst\u00e4ndige Elternmolek\u00fcl \u2013 f\u00fcr vergleichende Pharmakologie), <a href=\"https:\/\/medsbase.com\/de\/tesamorelin\/\">Tesamorelin<\/a> (GHRH-Analogon \u2013 upstream HGH-Achsen-Stimulation), <a href=\"https:\/\/medsbase.com\/de\/sermorelin\/\">Sermorelin<\/a> (GHRH 1-29 Analogon), und <a href=\"https:\/\/medsbase.com\/de\/mots-c\/\">MOTS-c<\/a> (mitochondriales metabolisches Peptid). Durchsuchen Sie das vollst\u00e4ndige <a href=\"https:\/\/medsbase.com\/de\/peptides\/\">peptides &amp; compounds catalog<\/a>, oder siehe die kuratierte <a href=\"https:\/\/medsbase.com\/de\/best-peptides-for-fat-loss\/\">fat-loss peptides<\/a> und <a href=\"https:\/\/medsbase.com\/de\/best-growth-hormone-peptides\/\">growth-hormone peptides<\/a> Hubs. <\/p>\n<h2>Verf\u00fcgbare St\u00e4rken und Konzentrationen<\/h2>\n<p>MedsBase stocks AOD-9604 in three lyophilized vial sizes calibrated to typical in-vitro and in-vivo protocols. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Vial-St\u00e4rke<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Typischer Anwendungsfall<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Packungsgr\u00f6\u00dfen<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>2 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">In-vitro-Zellkultur und kurzfristige in-vivo-Titration \u2014 3T3-L1-Adipozyten-Lipolyse-Assays, prim\u00e4re Adipozyten-Pharmakologie, Dosis-Wirkungs-Panels, Einzelkohorten-M\u00e4use-Titration<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 oder 30 Vials<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard mid-strength \u2014 diet-induced obesity rodent protocols (100\u2013500 \u00b5g\/kg\/d SC for 4\u20138 weeks), chondrocyte \/ osteoarthritis studies, multi-cohort sample sizes<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 oder 30 Vials<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">High-strength vial \u2014 extended-cycle \/ high-dose protocols (up to 1 mg\/kg\/d SC), large-cohort DIO studies, multi-arm structure-function comparisons; lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 oder 30 Vials<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical entity (lyophilized AOD-9604, \u226599% HPLC purity, MALDI-TOF mass-confirmed at 1815.1 Da). The 10\u00a0mg vial provides the lowest per-mg cost for large in-vivo protocols (a single 10\u00a0mg vial supports approximately 50 days of 200 \u00b5g\/kg\/d dosing in a 25-g mouse, or about 10 days at 1\u00a0mg\/kg\/d in a 30-g rat). Users should determine specific dose ranges from peer-reviewed literature appropriate to the protocol. <\/p>\n<h2>Vergleich \u2014 AOD-9604 vs HGH Fragment 176-191<\/h2>\n<p>AOD-9604 und <a href=\"https:\/\/medsbase.com\/de\/hgh-fragment-176-191\/\">HGH Fragment 176-191<\/a> are the two HGH C-terminal fragment peptides in this catalogue, and they sit very close together on the structure-function spectrum. AOD-9604 is the Metabolic-Pharmaceuticals-developed analogue with the N-terminal tyrosine extension that adds protease-stability. The un-stabilised HGH Fragment 176-191 lacks the N-terminal Tyr and has a slightly shorter half-life in culture \/ in-vivo, but is otherwise mechanistically identical. The two compounds are often used interchangeably in supplier listings \u2014 the differentiation matters for rigorous pharmacology studies, less so for cell-culture stimulation work. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Kriterium<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">AOD-9604<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">HGH Fragment 176-191<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>CAS-Nummer<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">221231-10-3<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">66004-57-7<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Sequenz (Ein-Buchstaben-Code)<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">YLRIVQCRSVEGSCGF (16 aa; mit N-terminaler Tyr-Stabilisierung)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">YLRIVQCRSVEGSCGF (16 aa) oder LRIVQCRSVEGSCGF (15 aa, nicht stabilisiert) je nach Lieferantencharge; COA konsultieren<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Molekulargewicht<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1815.1 g\/mol<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">1817,06 g\/mol (16-aa Lieferantenqualit\u00e4t) oder 1654 g\/mol (15-aa nicht stabilisiert)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Herkunft<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Metabolic Pharmaceuticals Ltd (Monash University, Australien, Ende der 1990er)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Earlier academic studies-peptide preparation, pre-dating AOD-9604<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Plasmahalbwertszeit<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~4 Minuten<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2\u20133 Minuten (k\u00fcrzer, weniger proteasestabil)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>GH-Rezeptorbindung<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Keine \u2013 bindet nicht an GHR\/JAK2\/STAT5\/IGF-1-Achse<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Keine \u2013 gleiche Eigenschaft; beide sind GHR-entkoppelte Fragmente<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Klinische Studienhistorie<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Phase-IIb-Adipositas-Studie (~500 Patienten, 2007) erreichte prim\u00e4ren Endpunkt nicht; Programm eingestellt<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Kein formelles klinisches Entwicklungsprogramm<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best applications<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Leicht bevorzugt f\u00fcr In-vivo-Arbeiten aufgrund der etwas l\u00e4ngeren Halbwertszeit; Referenzverbindung f\u00fcr Struktur-Funktions-Vergleiche<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">In-vitro-Zellkultur-Lipolyse-Assays, bei denen die kurze Halbwertszeit weniger einschr\u00e4nkend ist<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on rigorous structure-function HGH-fragment pharmacology, AOD-9604 with its registered CAS \/ known origin is the cleaner reference. For exploratory in-vitro lipolysis work where the precise origin matters less, <a href=\"https:\/\/medsbase.com\/de\/hgh-fragment-176-191\/\">HGH Fragment 176-191<\/a> is the more economical option. For studies that needs the full HGH pharmacology including GH-receptor \/ IGF-1 axis engagement, see <a href=\"https:\/\/medsbase.com\/de\/hgh-191aa\/\">HGH 191AA<\/a>. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Ben\u00f6tigen Sie BAC-Wasser?<\/strong> Die Rekonstitution jedes lyophilisierten Fl\u00e4schchens erfordert steriles bakteriostatisches Wasser. Kombinieren Sie dieses Produkt mit unserem <a href=\"\/de\/bac-water\/\"><strong>BAC-Wasser (Bakteriostatisches Wasser)<\/strong><\/a> \u2014 30 mL Mehrdosenfl\u00e4schchen, 0,9% Benzylalkohol-konserviert, USP-Qualit\u00e4t.<\/div>\n<h2>Lagerung und Rekonstitution<\/h2>\n<p><strong>Vor der Rekonstitution:<\/strong> Lagern Sie lyophilisierte Fl\u00e4schchen gek\u00fchlt bei 2\u20138 \u00b0C in der Originalverpackung f\u00fcr kurzfristige Arbeitsbest\u00e4nde. F\u00fcr die Langzeitlagerung frieren Sie unge\u00f6ffnete Fl\u00e4schchen bei \u221220 \u00b0C ein (stabil \u226536 Monate bei \u221220 \u00b0C; \u226518 Monate bei 2\u20138 \u00b0C). Die Cys7\u2013Cys14-Disulfidbr\u00fccke ist im lyophilisierten Zustand und w\u00e4hrend der kurzfristigen K\u00fchllagerung stabil. Vor Licht sch\u00fctzen. <strong>Rekonstitutionsverfahren:<\/strong> Injizieren Sie bakterostatisches Wasser an der Seitenwand des Fl\u00e4schchens (nicht direkt auf den lyophilisierten Kuchen). F\u00fcr ein 2 mg-Fl\u00e4schchen ergibt 1,0 mL L\u00f6sungsmittel eine 2 mg\/mL Arbeitsl\u00f6sung; 0,5 mL ergeben 4 mg\/mL. F\u00fcr ein 5 mg-Fl\u00e4schchen ergibt 1,0 mL 5 mg\/mL; 2,5 mL ergeben 2 mg\/mL. F\u00fcr ein 10 mg-Fl\u00e4schchen ergibt 1,0 mL 10 mg\/mL (die praktische L\u00f6slichkeitsgrenze in w\u00e4ssrigem Puffer); 5,0 mL ergeben 2 mg\/mL. AOD-9604 l\u00f6st sich schnell durch sanftes Schwenken bei Raumtemperatur \u2013 typischerweise innerhalb von 15\u201330 Sekunden. Nach der Rekonstitution das Fl\u00e4schchen bei 2\u20138 \u00b0C lagern und innerhalb von 30 Tagen verwenden. Vor Licht sch\u00fctzen. <strong>Vermeiden Sie wiederholte Gefrier-Tau-Zyklen von rekonstituiertem Material<\/strong> \u2013 kumulative Gefrier-Tau-Zyklen k\u00f6nnen zu einer Cys7\u2013Cys14-Disulfidverwirrung und teilweisen Aggregation f\u00fchren. Verwerfen Sie bei Tr\u00fcbung, Partikeln oder deutlicher Farbver\u00e4nderung. <\/p>\n<h2>H\u00e4ufig gestellte Fragen<\/h2>\n<h3>Was ist der Unterschied zwischen AOD-9604 und HGH Fragment 176-191?<\/h3>\n<p>AOD-9604 (CAS 221231-10-3) is the Metabolic-Pharmaceuticals-developed registered compound with an N-terminal tyrosine extension that adds amino-terminal protease-stability to the parent hGH 177\u2013191 fragment. &#8220;<a href=\"https:\/\/medsbase.com\/de\/hgh-fragment-176-191\/\">HGH Fragment 176-191<\/a>&#8221; (CAS 66004-57-7 per some references) is the earlier, un-stabilised version of the same C-terminal hGH peptide. The two are often used interchangeably in the studies-peptide marketplace, but strictly the AOD-9604 designation identifies the Metabolic-Pharmaceuticals registered analogue with the stabilising Tyr. Both lack GHR binding and both retain the lipolytic activity of the parent hGH C-terminal region. Consult the COA to confirm which sequence form a given batch corresponds to. <\/p>\n<h3>Ist AOD-9604 dasselbe wie HGH?<\/h3>\n<p>Nein. AOD-9604 ist ein 16-Aminos\u00e4uren-synthetisches Fragment von HGH, das nur die C-terminale lipolytische Region abdeckt (Residuen 176\u2013191 + N-terminales Tyr). Natives <a href=\"https:\/\/medsbase.com\/de\/hgh-191aa\/\">HGH 191AA<\/a> is the full-length 191-amino-acid protein. The most important pharmacological difference is that full-length HGH binds the growth hormone receptor (GHR) and activates the JAK2\/STAT5\/IGF-1 axis \u2014 driving the broad growth-promoting and metabolic effects of HGH \u2014 while AOD-9604 does NOT bind GHR and does NOT induce IGF-1. AOD-9604 retains only the lipolytic \/ anti-lipogenic activity of the parent molecule. The two compounds are therefore mechanistically distinct: HGH 191AA for full GH-axis pharmacology, AOD-9604 for lipolysis-only studies. <\/p>\n<h3>Warum ist die Phase-IIb-Adipositas-Studie gescheitert?<\/h3>\n<p>The 28-week Phase IIb obesity trial (~500 patients, completed by Metabolic Pharmaceuticals in 2007) did not achieve its primary weight-loss endpoint relative to placebo. The leading hypotheses in subsequent published analyses are: (1) the very short plasma half-life (~4 minutes) limits cumulative receptor exposure under once-daily SC dosing; (2) the lipolytic effect, while real in mechanistic in-vitro and acute in-vivo experiments, may not translate to net adipose-mass loss in the human metabolic context where compensatory anti-lipolytic signalling dominates over chronic dosing; (3) the in-vivo dose may have been insufficient to overcome the pharmacokinetic constraint. The compound was repositioned for osteoarthritis studies after the obesity programme was discontinued. <\/p>\n<h3>What published dose ranges have been used in rodent studies?<\/h3>\n<p>Published mouse and rat in-vivo protocols typically use 100\u20131,000 \u00b5g\/kg\/d SC, with most published work in the 200\u2013500 \u00b5g\/kg\/d range for 4\u20138 weeks. The higher end of this range (up to 1 mg\/kg\/d) has been used in some publications to overcome the short half-life. In-vitro 3T3-L1 adipocyte assays typically use 1\u201310 \u00b5M. Users should consult primary literature (Ng et\u00a0al. \u2014 Metabolic Pharmaceuticals studies; Heffernan et\u00a0al. \u2014 adipocyte mechanism studies) for species-, model-, and endpoint-specific guidance. <\/p>\n<h3>Wie ist der WADA-Regulierungsstatus von AOD-9604?<\/h3>\n<p>AOD-9604 is not on the current WADA Prohibited List under its specific name. However, the broader S2 class (Peptide Hormones, Growth Factors, Related Substances and Mimetics) explicitly covers growth-hormone fragments and &#8220;GH-axis-related compounds,&#8221; and AOD-9604&#8217;s classification under this broader category has been the subject of regulatory discussion. Users conducting human-subject studies with AOD-9604 should consult the current WADA Prohibited List and applicable jurisdictional regulations directly rather than relying on the absence of a specific name from the list. <\/p>\n<h3>Was ist der Unterschied zwischen AOD-9604 und direkten \u03b23-adrenergen Agonisten wie Mirabegron?<\/h3>\n<p>Mirabegron und CL-316,243 sind <em>direkter<\/em> \u03b23-adrenerge Rezeptoragonisten \u2014 kleine Molek\u00fcle, die die orthosterische Bindungsstelle des \u03b23-AR binden und die Gs-cAMP-Signalgebung aktivieren. AOD-9604 ist ein <em>indirekter<\/em> \u03b23-AR engager (in some published studies) \u2014 the lipolytic activity is blunted by \u03b23-AR antagonists, supporting \u03b23-AR-dependence, but direct AOD-9604 \/ \u03b23-AR binding has not been conclusively demonstrated. For studies that needs cleanly defined direct \u03b23-AR pharmacology, mirabegron or CL-316,243 are the preferred tools. For studies that needs the broader &#8220;lipolytic-fragment-of-HGH&#8221; pharmacology with its incompletely-characterised mechanism, AOD-9604 is the canonical reference. <\/p>\n<h3>Can AOD-9604 be combined with HGH 191AA, GHRH analogues, or other lipolytic peptides in protocols?<\/h3>\n<p>Ja \u2014 AOD-9604 zielt auf eine andere Ebene der HGH-Achsen-Biologie ab als das vollst\u00e4ndige <a href=\"https:\/\/medsbase.com\/de\/hgh-191aa\/\">HGH 191AA<\/a> oder die GHRH-Analoga (<a href=\"https:\/\/medsbase.com\/de\/tesamorelin\/\">Tesamorelin<\/a>, <a href=\"https:\/\/medsbase.com\/de\/sermorelin\/\">Sermorelin<\/a>), and combinations are commonly used in published studies to dissect lipolytic-only contributions from broader GH-axis effects. The most-published combinations are AOD-9604 + HGH 191AA (testing whether the lipolytic component adds to or substracts from full HGH activity); AOD-9604 + <a href=\"https:\/\/medsbase.com\/de\/mots-c\/\">MOTS-c<\/a> (dual fat-loss studies, different mechanisms); AOD-9604 + a GHRH analogue (testing whether endogenous-pulsatile HGH release combined with the lipolytic fragment outperforms either alone). Reconstitute each separately and follow each compound&#8217;s specific storage rules. <\/p>\n<h3>Warum wird AOD-9604 manchmal mit 1815,1 Da und manchmal mit 1817 Da angegeben?<\/h3>\n<p>Die Diskrepanz spiegelt den Unterschied zwischen monoisotopischer Masse (1815,1 Da, berechnet aus dem h\u00e4ufigsten Isotop jedes Atoms) und durchschnittlicher Molek\u00fclmasse (1817,1 Da, berechnet aus dem nat\u00fcrlichen isotopengewichteten Durchschnitt jedes Atoms) wider. Beide sind f\u00fcr dasselbe Molek\u00fcl korrekt. MALDI-TOF-Massenspektrometrie gibt typischerweise monoisotopische Masse f\u00fcr Peptide dieser Gr\u00f6\u00dfe an; \u00e4ltere Literatur und einige Lieferanten geben die Durchschnittsmasse an. F\u00fcr COA-Zwecke ist der Wert von 1815,1 Da der kanonische Sigma-Aldrich-Referenzwert. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for HGH-Axis and Fat-Loss Studies<\/h2>\n<ul>\n<li><a href=\"\/de\/hgh-fragment-176-191\/\"><strong>HGH Fragment 176-191<\/strong><\/a> \u2014 Nicht-stabilisiertes Elternfragment \u2014 direkter mechanistischer Verwandter, \u00e4hnliche GHR-entkoppelte Lipolyse<\/li>\n<li><a href=\"\/de\/hgh-191aa\/\"><strong>HGH 191AA<\/strong><\/a> \u2014 Vollst\u00e4ndiges Elternmolek\u00fcl \u2014 f\u00fcr vergleichende Pharmakologie mit GH-Achsen-Engagement<\/li>\n<li><a href=\"\/de\/tesamorelin\/\"><strong>Tesamorelin<\/strong><\/a> \u2014 GHRH-Analogon \u2014 upstream HGH-Achsen-Stimulation<\/li>\n<li><a href=\"\/de\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 GHRH 1-29 analogue \u2014 pituitary endogenous-HGH studies<\/li>\n<li><a href=\"\/de\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Mitochondrial-derived metabolic peptide \u2014 alternative-mechanism fat-loss studies<\/li>\n<li><a href=\"\/de\/bac-water\/\"><strong>BAC-Wasser (Bakteriostatisches Wasser)<\/strong><\/a> \u2014 Erforderlich zur Rekonstitution lyophilisierter Fl\u00e4schchen \u2014 steriles, 0,9% Benzylalkohol-konserviertes L\u00f6sungsmittel<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Stabilisiertes hGH 176-191 C-terminales lipolytisches Fragment (N-terminale Tyr-Verl\u00e4ngerung)<br \/>\n\u2705 Entwickelt von Metabolic Pharmaceuticals Ltd (Monash University, Ende der 1990er Jahre)<br \/>\n\u2705 GHR-entkoppelt \u2014 kein IGF-1, kein JAK2\/STAT5, keine Wachstumsachsenaktivierung<br \/>\n\u2705 Lipolytisch + anti-lipogen; \u03b23-AR-abh\u00e4ngig (Mechanismus nicht vollst\u00e4ndig charakterisiert)<br \/>\n\u2705 ~4 min Plasmahalbwertszeit; Phase IIb Adipositas-Studie gescheitert (2007); MW 1815.1, CAS 221231-10-3<\/p>\n<p><strong>AOD-9604<\/strong> contains synthetic Tyr-hGH(177-191) peptide.<\/p>","protected":false},"featured_media":71463,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6500,6499,6502,6503,6289,6501,6494],"class_list":["post-71446","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-anti-obesity-drug","product_tag-aod-9604","product_tag-fat-loss-research","product_tag-ghr-decoupled","product_tag-hgh-fragment","product_tag-lipolytic-peptide","product_tag-research-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product\/71446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/comments?post=71446"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/media\/71463"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/media?parent=71446"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product_brand?post=71446"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product_cat?post=71446"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/de\/wp-json\/wp\/v2\/product_tag?post=71446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}